Corgenix to Launch New Hepcidin-25 Product at the American Society of Hematology Annual Meeting

First product developed in Corgenix collaboration with Lilly

Business Wire


Corgenix Medical Corporation (CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it will launch the Research-Use-Only (RUO) Hepcidin-25 Chemiluminescent Direct ELISA test kit at the 55th Annual Meeting of the American Society of Hematology (ASH®) at the Ernest N. Morial Convention Center in New Orleans. The test kit is based on technology originally developed at Eli Lilly and Company and licensed for further development by Corgenix.

“The ASH annual meeting is the ideal strategic launching pad for important new products related to anemia and cancer; therefore, it is a natural choice for us to launch the new Hepcidin-25 RUO product at this prestigious event,” said Douglass Simpson, President and CEO of Corgenix. “We are very pleased to be able to introduce this high quality test kit to the global research community, opening a new door for Corgenix.”

Hepcidin, a hepatic peptide hormone, is a key regulator of iron metabolism. Hepcidin deficiency has been linked to hemochromatosis and iron overload, whereas increased concentrations have been reported in anemia of cancer and other chronic diseases. The new technology enables the measurement of serum concentrations of hepcidin-25, the active form of the hormone.

To learn more about the Hepcidin-25 Chemiluminescent Direct ELISA test kit, please visit the Company's booth # 3921 at the ASH meeting, December 7-10, 2013. The Hepcidin-25 Chemiluminescent Direct ELISA test kit has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic purposes.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at

About the American Society of Hematology

The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and treatments of blood disorders. The mission of the Society is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Company Contact:
Corgenix Medical Corp
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President, Public Relations Supervisor


View Comments (0)